Stable solid, crystalline forms of elsamitrucin salts are provided that
are useful in preparing anti-neoplastic parenteral formulations. Also
provided are methods for treating neoplastic diseases in humans using
parenteral formulations that include at least one stable elsamitrucin
salt.